Pharming Group N.V.
PHAR
NASDAQ·Healthcare·Biotechnology·Mkt cap $794.8M
$11.23
▼ -2.01%
P/E
-215.96
Mkt Cap
$794.8M
52-Wk Range
$9.62–$21.34
52-Week Range
$9.62 - $21.34
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 22.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.1).
- High premium - requires strong execution
Growth
Turning profitable
Value
High premium - requires strong execution
Momentum
Weak
-10.4% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PHAR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
JUL 30, 2026
Reported EPS of $0.02 vs $0.06 consensus (-68.3% surprise). Revenue of $90.2M vs $99.5M expected (-9.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-68.3%
Revenue trend · last 2Q
—
-3%
Q1 26
Q2 26
$72.7M
$90.2M
Margins · last 2Q
Gross
83.9%
Operating
-0.1%
Profit
1.8%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · $40.00 · May 8, 2026
vs Industry
How PHAR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.